- STAAR has a 20% 5-year average of year over year revenue growth and high gross margins of 77.5% for 2021 and 72.4% for 2020.
- Used to treat hyperopia, myopia, and astigmatism, their product has been implanted in more than 1M eyes spanning across 75 plus countries.
- On the 28th of March, the U.S. FDA approved STAAR EVO/EVO+ Visian Implantable Collamer Lens.
- 75 percent of adult Americans have a visionary problem that requires correction. That is an estimated number of nearly 230M people in the U.S.
For further details see:
Is STAAR Surgical A Watchlist Contender?